Literature DB >> 32487532

Primary Sjogren's syndrome manifesting with distal renal tubular acidosis and severe metabolic bone disease.

Gitanjali Jain1, Suprita Kalra2, Gautam Vasnik3, Sumit Bhandari4.   

Abstract

Sjogren's syndrome (SS) is a chronic, autoimmune, inflammatory disorder affecting primarily the salivary and lacrimal glands with potential for systemic involvement. The disease predominantly occurs in women in the age group of 35-45 years and is relatively rare in children. It mainly affects salivary and lacrimal glands with potential for systemic involvement. Children presenting with the severe metabolic bone disease at the very outset has not been reported in the paediatric literature. We report a 13-year-old girl who presented with pain in multiple large joints with predominant involvement of hip joints leading to difficulty in walking for the past 6 months and unintentional weight loss of the same duration. Investigations revealed distal renal tubular acidosis with severe metabolic bone disease as an extra-glandular manifestation of primary SS. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  musculoskeletal and joint disorders; paediatrics (drugs and medicines)

Mesh:

Substances:

Year:  2020        PMID: 32487532      PMCID: PMC7265001          DOI: 10.1136/bcr-2020-234929

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  The spectrum of renal tubular acidosis in paediatric Sjögren syndrome.

Authors:  F Pessler; H Emery; L Dai; Y-M Wu; B Monash; R Q Cron; M Pradhan
Journal:  Rheumatology (Oxford)       Date:  2005-09-13       Impact factor: 7.580

Review 2.  The Diagnosis and Treatment of Sjögren's Syndrome.

Authors:  Ana-Luisa Stefanski; Christian Tomiak; Uwe Pleyer; Thomas Dietrich; Gerd Rüdiger Burmester; Thomas Dörner
Journal:  Dtsch Arztebl Int       Date:  2017-05-26       Impact factor: 5.594

3.  Osteomalacia secondary to renal tubular acidosis due to Sjögren's syndrome: a case report and review of the literature.

Authors:  Hiroshi Nagae; Yuko Noguchi; Shinako Ogata; Chinami Ogata; Rei Matsui; Yukiko Shimomura; Ritsuko Katafuchi
Journal:  CEN Case Rep       Date:  2012-08-15

4.  Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients.

Authors:  Norma Nardi; Pilar Brito-Zerón; Manuel Ramos-Casals; Sira Aguiló; Ricard Cervera; Miguel Ingelmo; Josep Font
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

5.  Acquired hypophosphatemia osteomalacia associated with Fanconi's syndrome in Sjögren's syndrome.

Authors:  Yi-Sun Yang; Chiung-Huei Peng; Sung-Kien Sia; Chien-Ning Huang
Journal:  Rheumatol Int       Date:  2006-11-09       Impact factor: 2.631

6.  The urine-blood PCO gradient as a diagnostic index of H(+)-ATPase defect distal renal tubular acidosis.

Authors:  Sejoong Kim; Jay Wook Lee; Junghwan Park; Ki Young Na; Kwon Wook Joo; Curie Ahn; Suhnggwon Kim; Jung Sang Lee; Gheun-Ho Kim; Jin Kim; Jin Suk Han
Journal:  Kidney Int       Date:  2004-08       Impact factor: 10.612

7.  Renal tubular acidosis, Sjögren syndrome, and bone disease.

Authors:  Milford Fulop; Meggan Mackay
Journal:  Arch Intern Med       Date:  2004-04-26

8.  Osteomalacia as inaugural manifestation of Sjögren syndrome.

Authors:  Eya Cherif; Lamia Ben Hassine; Zouleikha Kaoueche; Narjess Khalfallah
Journal:  BMJ Case Rep       Date:  2013-10-09

Review 9.  A child with primary Sjögren syndrome and a review of the literature.

Authors:  Mahmut Civilibal; Nur Canpolat; Ayse Yurt; Sebuh Kurugoglu; Sibel Erdamar; Onur Bagci; Lale Sever; Ozgur Kasapcopur; Salim Caliskan; Nil Arisoy
Journal:  Clin Pediatr (Phila)       Date:  2007-05-16       Impact factor: 1.168

Review 10.  A systematic review of primary Sjögren's syndrome in male and paediatric populations.

Authors:  Simrun Virdee; James Greenan-Barrett; Coziana Ciurtin
Journal:  Clin Rheumatol       Date:  2017-07-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.